HYMAN CHAI, M.D.; LEIZER MOLK, M.D.; ELLIOTT MIDDLETON JR., M.D.
This content is PDF only. Please click on the PDF icon to access.
The appearance of any new drug for the control of bronchial asthma excites both physician and patient alike, for even the most modern management of severe asthma still leaves much to be desired. A new possibility for improved pharmacologic control is the compound disodium cromoglycate (DSC, FPL670, "Intal"). Disodium cromoglycate is a member of the "chromone" class of compounds and is a chemical relative of khellin, a plant-derived substance known to have bronchodilator properties (1, 2).
Of a number of compounds in the chromone series, DSC was found to be the most active in protecting against experimentally induced asthma (3),
CHAI H, MOLK L, MIDDLETON E. Disodium Cromoglycate in Bronchial Asthma. Ann Intern Med. 1969;71:1212–1214. doi: https://doi.org/10.7326/0003-4819-71-6-1212
Download citation file:
Published: Ann Intern Med. 1969;71(6):1212-1214.
Asthma, Pulmonary/Critical Care.
Results provided by:
Copyright © 2019 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use